Excellerate Bioscience, based at Biocity Nottingham, is pleased to announce the appointment of four new scientists and senior scientists to deliver additional project support for our international client preclinical drug discovery programmes; Dr Kazuyo Kaneko, Dr James Wood, Lily Morley and Alice Nottingham.
Left to right: Kazuyo Kaneko, Alice Nottingham, Lily Morley, James Wood
Kazuyo joins as a Senior Immunologist with 12 years postdoctoral experience in immunology. She most recently worked at OMassTherapeutics where she led target validation for various projects. Commenting on her appointment at Excellerate Bioscience, Kazuyo said “I am very excited to be a part of the dynamic team and look forward to bringing my expertise and experience to accelerate client drug discovery programmes”.
James joins Excellerate as a Senior Scientist following a post-doc at the University of Edinburgh, where he studied the interplay between metabolism and epigenetics in cancer. His particular interest in cellular metabolism developed during his PhD from his research into the dependency of brain tumours on lipoproteins for growth and survival.
Lily and Alice join the team at Scientist I level. Lily previously worked at both Oncimmune in R&D ELISA development and COVID diagnostics at Source Bioscience, following her MSci in Biochemistry and Genetics at the University of Nottingham. She has a keen interest in oncology and immuno-oncology research. Alice has just completed her MSci in Biochemistry and Biological Chemistry at the University of Nottingham, commenting “I am excited to join the team at Excellerate and learn more about pharmacology and assay development. I look forward to working on new projects and being able to apply what I have learnt at university within an industry setting.”
Nick Holliday, CSO of Excellerate Bioscience, added “We welcome Kazuyo, James, Alice and Lily to the team, and are delighted to recruit such talented individuals full of potential to the Excellerate family. They will make a strong addition to our team of creative and collaborative scientists working on our portfolio of client drug discovery programs in molecular and cellular pharmacology and immunology”.